{"entity":{"id":"enliven-therapeutics","kind":"company","name":"Enliven Therapeutics","aka":[],"tldr":"Enliven Therapeutics designs cleaner versions of cancer pills that already work. Its lead drug targets the BCR-ABL protein in chronic myeloid leukaemia and a second drug targets mutated HER2 in lung cancer.","summary":"Enliven Therapeutics is a Boulder, Colorado clinical-stage precision oncology company developing next-generation small molecule kinase inhibitors intended to improve tolerability, combinability and resistance coverage. ELVN-001 is a potent, highly selective BCR-ABL inhibitor that binds a distinctive folded-in P-loop conformation of ABL1 and is in clinical development for chronic myeloid leukaemia (CML). ELVN-002 is a selective, irreversible HER2 inhibitor with activity against HER2 mutations including exon 20 insertions in non-small cell lung cancer, in phase 1. Enliven became a Nasdaq company in February 2023 by merging with Imara Inc., closing a concurrent 165 million US dollar private placement co-led by Fairmount and Venrock Healthcare Capital Partners; shares trade as ELVN.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.enliventherapeutics.com/"},{"label":"Pipeline","url":"https://www.enliventherapeutics.com/pipeline/"},{"label":"Merger closing and private placement (SEC exhibit)","url":"https://www.sec.gov/Archives/edgar/data/1672619/000119312523056303/d464771dex991.htm"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":["targeted-therapy"],"technologies":["kinase-inhibitors"],"targets":["her2"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Chronic myeloid leukaemia has no id in the cancer list so is not tagged. Pre-merger venture rounds and founding year not sourced."],"hq":"Boulder, CO","country":"US","companyType":"biotech","website":"https://www.enliventherapeutics.com/","ticker":"ELVN","stage":"public","investors":["venrock","ra-capital","frazier-life-sciences"],"funding":[{"round":"Crossover","year":2023,"amountUsd":165000000,"source":"https://www.sec.gov/Archives/edgar/data/1672619/000119312523056303/d464771dex991.htm","note":"165 million US dollar private placement closed concurrently with the reverse merger into Imara (Nasdaq: ELVN) on 23 February 2023"}]},"route":"/companies/enliven-therapeutics/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"}],"company":[{"id":"5am-ventures","kind":"company","name":"5AM Ventures","route":"/companies/5am-ventures/"},{"id":"frazier-life-sciences","kind":"company","name":"Frazier Life Sciences","route":"/companies/frazier-life-sciences/"},{"id":"ra-capital","kind":"company","name":"RA Capital Management","route":"/companies/ra-capital/"},{"id":"venrock","kind":"company","name":"Venrock","route":"/companies/venrock/"}]}}